Immune
Thymosin Alpha-1 Benefits: Immune Help or Hype?
Approved medicine abroad with a mixed, recently weaker trial record.
The quick version
- An immune peptide, sold abroad as Zadaxin, not FDA approved.
- Mixed record; the largest 2025 sepsis trial found no clear benefit.
- Weak case for a healthy person chasing immunity.
What it is
Thymosin alpha-1 is an immune-signaling peptide. Sold as Zadaxin in many countries, it is used for hepatitis and immune support, though it is not FDA approved in the US.
What the research shows
The evidence is mixed. It is approved in 35-plus countries and older meta-analyses suggested a survival benefit in sepsis, but the largest trial to date, a 1106-patient phase 3 in 2025, found no clear drop in deaths (TESTS trial, 2025). It clearly does something to the immune system, but the hard outcome data is shaky.
What it felt like
I have not run thymosin alpha-1. It sits more in the clinical-treatment lane than the self-experiment one, so I am going off the trial record here.
Dosing reality
Clinical use of Zadaxin is commonly 1.6 mg under the skin twice a week, which is one of the clearer dose references in this space. Off-label hobby use copies that, without the medical oversight that came with the trials.
The one mistake to avoid
The mistake is buying it as a general immune booster for a healthy person. The trials were in sick patients, and even there the latest big one came up short.
Bottom line
Thymosin alpha-1 is real medicine abroad with a mixed trial record. For a healthy person chasing immunity, the case is weak.
Reminder: I am not a doctor and this is not medical advice. It is my own notes and reading of the research. Peptides sit in a legal grey area, research-grade is a real category, and it is on you to verify your own compliance. Talk to a qualified professional before you start anything, especially if you take other medication.